ArticleScientific reports2025
Circulating gamma-glutamyl transpeptidase, systemic inflammation biomarkers and risk of lung cancer in the UK biobank prospective cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From Gene to Enzyme: Multidimensional Decoding of the GGT Molecular Family and Its Clinical Tumor Diagnosis.Cancer medicine · 2025Pooled it
- Systemic inflammatory indices and lung cancer risk by smoking and alcohol use in Korean men: A secondary dataset analysis of the Korean Cancer Prevention Study-II.Tobacco induced diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Epidemiological evidence on the association between Gamma-glutamyl transpeptidase (GGT) and lung cancer risk is limited. Meanwhile, whether inflammation can modify the association of GGT-lung cancer remains unknown. We assessed the relationship of GGT-lung cancer and modification effects of inflammation biomarkers in 412,634 participants from UK Biobank using Cox models and interactive analysis. This study founds participants in the top quartile of GGT level had an increased risk of lung cancer by 45.1% (HR, 1.451; 95% CI, 1.299-1.621; p < 0.001) compared to those in the bottom quartile. Positive associations were also observed between inflammation biomarkers (lymphocyte, neutrophil, platelet, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, white blood cell [WBC], C-reactive protein [CRP]) and lung cancer risk. Meanwhile, we observed the WBC and CRP served varying modification effects on the GGT-lung cancer associations (p
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.